7-OH Labels: How to Separate Product Facts From Marketing

By UltimateKratom.com Research Desk

Editorial independence: UltimateKratom.com is an independent publication. It is not a medical provider and has no clinic or institutional affiliation. This article contains no affiliate links and no product recommendations. Other pages on this site may carry affiliate disclosures. Sources last checked October 6, 2026.

The short answer: sort every line on a 7-OH listing or package into one of two buckets. A disclosure is something you can check, such as what the ingredient is, how much of each alkaloid is in a serving, which lab tested which lot, and who the seller is. A promise is a word about how the product feels, how natural it is, how clean it is, or whether it is legal. Promises cannot establish safety or legality. In its August 2026 scheduling order, DEA criticized several of these same marketing words on products sold as 7-OH derivatives. The worksheet below helps you tell the two apart.

Why 7-OH labels deserve a closer read

7-hydroxymitragynine (7-OH) occurs naturally in the kratom plant, but FDA describes it as a minor constituent, less than 2% of the total alkaloid content in natural leaves. FDA also states that 7-OH shows substantially greater mu-opioid receptor potency than mitragynine, the plant's primary alkaloid, and than classical opioids such as morphine (FDA, “FDA and Kratom”).

That gap is why the word “7-OH” on a label can mean very different things. Federal agencies have said their recent actions target concentrated and synthetic 7-OH products, not natural kratom leaf containing only naturally occurring trace levels (FDA, “Hiding in Plain Sight: 7-OH Products,” July 13, 2026 update). A trustworthy listing should make clear which kind of product it is describing. If it doesn't, that is missing information, not a detail to assume away.

The claim-versus-disclosure worksheet

Go through a listing or package line by line. For each claim you find, look for the matching disclosure. If you can't find one, write “not disclosed.” That blank is information in itself. Where this worksheet cites DEA, the findings concern products sold as mitragynine pseudoindoxyl and MGM-15, which are 7-OH-related compounds. They are not findings about every 7-OH product.

• Claim: “Natural,” “botanical,” or “plant-based.”
  • Disclosure to look for: what the ingredient actually is (ground leaf, an extract, a concentrate, or something chemically converted) and how it was made.
  • What the claim can't establish: lower risk. DEA said that marketing semi-synthetic opioid products as “botanical extracts” creates a false sense of safety for consumers who equate “botanical” with lower risk (Federal Register, 91 FR 54948).
• Claim: “Kratom.”
  • Disclosure to look for: each alkaloid named with an amount, not just the word “kratom.”
  • What the claim can't establish: what is in the product. DEA noted that concentrated alkaloid products marketed as “kratom” often contain more than one opioid-active alkaloid. In one study of products sold as mitragynine pseudoindoxyl, 71 percent also contained 7-OH (Federal Register, 91 FR 54948).
• Claim: “Potent,” “fast-acting,” or “strong.”
  • Disclosure to look for: the amount of 7-OH per serving and per package, in milligrams, plus a clear definition of one serving. DEA observed that serving sizes on these products varied and often required consumers to split tablets (Federal Register, 91 FR 54948).
  • What the claim can't establish: how much is too much. Nothing on a label can tell you how a specific person will respond.
• Claim: “Lab tested” or “third-party tested.”
  • Disclosure to look for: who ran the test, which lot it covers, what it measured, and the date. A result for a different lot, or for only one alkaloid, says little about the item in your hand.
  • What the claim can't establish: that the product is safe. FDA has warned about kratom products contaminated with Salmonella and concerning levels of heavy metals (FDA, “FDA and Kratom”), so a potency-only test leaves those questions open.
• Claim: “For research purposes only” or “not for human consumption.”
  • Disclosure to look for: whether the rest of the listing (flavors, chewable tablets, serving instructions) matches that statement. DEA described “research chemical” labeling on flavored chewable products as a common tactic to bypass regulatory oversight (Federal Register, 91 FR 54948).
  • What the claim can't establish: that the product has been reviewed or approved for any use. It points the other way: the listing is telling you nobody has.
• Claim: Mood, calm, focus, or pain-relief language.
  • Disclosure to look for: any cited human research. FDA says there are no legally marketed drug products containing kratom or its known alkaloids, that it warns against kratom for medical treatment, and that few well-designed studies have given kratom to humans (FDA, “FDA and Kratom”).
  • What the claim can't establish: any benefit. Treat it as a promise, not a fact.
• Claim: A “Supplement Facts” panel or “dietary supplement” wording.
  • Disclosure to look for: nothing a panel can fix. FDA states that kratom is not lawfully marketed as a dietary supplement (FDA, “FDA and Kratom”).
  • What the claim can't establish: lawful status or regulatory review. A panel is a format, not an approval.
• Claim: “Legal,” “compliant,” or “legal in all 50 states.”
  • Disclosure to look for: a date, the specific compound, and the jurisdiction. Legal status here is changing and varies by place. FDA notes that states may have their own regulations or prohibitions and points to state health and law enforcement agencies as the best resource (FDA, “FDA and Kratom”).
  • What the claim can't establish: current legality. A seller's statement is a marketing claim, not a legal ruling.

What a label still can't tell you

Even a fully disclosed listing leaves real unknowns. FDA says mitragynine and 7-OH bind to the same brain receptors as opioid drugs such as codeine, and may produce classic opioid-related effects such as sedation, nausea and vomiting, constipation, physical dependence and withdrawal, and respiratory depression that may lead to death. FDA adds that the ability to cause harm depends on how much is taken and under what conditions (FDA, “FDA and Kratom”). No label can resolve that for an individual.

Basic research questions are also open. As of that FDA page's December 2, 2025 date, a well-designed human abuse potential study had not been conducted, and FDA reported awarding a grant for one in September 2024. So the abuse potential of kratom, mitragynine, and 7-OH was described as not yet fully understood (FDA, “FDA and Kratom”).

Verify current policy before you rely on anything

This area is moving quickly, so any article, including this one, can go stale. Before you rely on a listing's legal or safety statements:

1. Check the date on the listing's legal statement. If it has none, treat it as unverified.
2. Read FDA's current 7-OH page for its latest update. As of its July 13, 2026 update, DEA had begun a temporary scheduling process for 7-OH above a proposed threshold, and HHS had opened a 30-day comment period on that threshold. The same update says HHS asked whether other ways of expressing the threshold should be used, so check which unit a listing uses (percent of weight or milligrams) before comparing it to anything.
3. Search the Federal Register for “7-hydroxymitragynine” to see whether a final order has published for 7-OH. The August 26, 2026 order covered three related compounds, not 7-OH itself, and it runs through August 26, 2028. The official edition is the govinfo PDF (Federal Register, 91 FR 54948).
4. Ask your state health department or state law enforcement agency about state rules, since FDA names them as the best resource.
5. Compare the listing's compound names against current scheduling notices. Some are sold under other names: the August order lists MGM-15 as also known as dihydro-7-hydroxymitragynine.

Who should talk to a professional

• Anyone who takes prescription medications, has a health condition, or is pregnant should ask a pharmacist or clinician. FDA reports cases of neonatal abstinence syndrome after prolonged prenatal exposure to kratom (FDA, “FDA and Kratom”).
• Anyone worried about dependence or withdrawal should speak with a clinician. FDA describes cases of kratom-related substance use disorder, including withdrawal symptoms when use was stopped (FDA, “FDA and Kratom”).
• If you think someone is having a bad reaction to a 7-OH product, call the Poison Help Line at 1-800-222-1222, or 911 for a life-threatening emergency (FDA). You can also report adverse events to FDA through MedWatch.

Keep reading

For the wider picture, see our overview of kratom research, regulatory status, and safety concerns and our guide to kratom drug interactions and dependence risk.

General education only. This article does not recommend, rank, or advise on using any product, and it makes no benefit, dosing, safety, or legal guarantee.

Sources

• U.S. Food and Drug Administration, “FDA and Kratom” (page dated December 2, 2025; checked October 6, 2026)
• U.S. Food and Drug Administration, “Hiding in Plain Sight: 7-OH Products” (July 13, 2026 update; checked October 6, 2026)
• Drug Enforcement Administration, Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I, 91 FR 54948 (August 26, 2026; checked October 6, 2026; official PDF)